Molecular Profiling for Risk Stratification in Appendiceal Cancer
Key facts
- Who runs it
- City of Hope Medical Center
- Where
- Durate, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 1 May 2026
- Expected to end
- 1 Jan 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- DNA Methylation Profiling
- m6A Epitranscriptomic Profiling
- Record updated
- 29 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer
- Availability of archived tumor tissue suitable for molecular profiling
- Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both
- Availability of relevant clinicopathologic data
- Availability of survival or follow-up information when applicable
- Age 18 years or older at diagnosis or tissue collection
Who cannot take part
- Insufficient tissue quantity or quality for molecular profiling
- Inadequate DNA or RNA quality for sequencing or molecular assay preparation
- Missing essential clinicopathologic information required for analysis
- Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site
- Patients who do not meet institutional review board or consent requirements, if applicable
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Appendiceal cancer
This trial is currently available in United States.
- City of Hope Medical CenterDurate, United StatesContact: Ajay Goel, MDTaking people
About the trial
What the trial wants to find out
This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.
The 2 groups in the trial
- Appendiceal Cancer Cohort
Patients with histologically confirmed appendiceal cancer whose archived tumor tissue specimens and clinicopathologic data are available for integrated DNA methylation and m6A epitranscriptomic profiling.
Treatment: DNA Methylation Profiling and m6A Epitranscriptomic Profiling
- Benign Appendix Reference Cohort
Individuals with benign or normal appendix tissue specimens used as non-malignant reference samples for comparison of tumor-associated DNA methylation and m6A epitranscriptomic features.
Treatment: DNA Methylation Profiling and m6A Epitranscriptomic Profiling
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Molecular Profiling for Tumor Characterization and Risk Stratification in Patients With Appendiceal Cancer
- Criteria questions
- Built from NCT07587268, who can take part
- Record updated
- 29 June 2026